
German HTGF IV fund closes at €493m
Alongside the Federal Ministry of Economics and Climate Protection (BMWK) and KfW Capital, 45 private investors (companies) participated in HTGF IV...

Neurodegenerative disorders are being fought with €28m
The Danish biotech Teitur Trophics ApS, aiming to treat chronic neurological disorders, has completed a €28m Series A funding. With the money, Teitur...

Stem cell gene transfer treats IL-1 immune diseases
Dysregulation of the interleukin-1 (IL-1) pathway leads to immune diseases that can result in chronic tissue and organ inflammation. Although IL-1...

Wacker AG expands biotech business through €100m acquisition
Following Wacker’s purchase of fermentation assets in the northern Spanish city of León in 2016, the chemical group now owns the entire site. The...

Hot of the press: new issue of BIOTECH Insight
The current issue of the BIOTECH Insight Newsletter, launched in December 2021 by Deutsche Börse with support of BIOCOM AG, addresses hot topics in...

Tay Therapeutics in licensing deal with VYNE Therapeutics
Tay Therapeutics Ltd’s exclusive license deal with VYNE Therapeutics Inc. on the oral BET inhibitor, TAY-B2 (now known as VYN201) forsees an upfront...

Upscaling AAV gene therapy
Mid-March marks the start of the collaboration of Remedium Bio Inc. and Biovial Oy on an AAV gene therapy for osteoarthritis. Rheumatology and...